Who
Gilbert F. Amelio
Director
Company insider
Files Form 4 as: Director, Galectin Therapeutics; Director, InterDigital; Director, 5BARz International; Director, At&t; Chairman and CEO, Jazz Technologies.
In numbers
- Trades disclosed
- 126
- Buys
- 5
- Sells
- 9
- Bought
- $73.5B
- Sold
- $754K
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 31 Jan 2006
- Last trade
- 16 Jan 2026
- Last filed
- 21 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 24 Jan 2024filed 7 Feb 2024 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 26 Jan 2023filed 30 Jan 2023 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 24 Jan 2022filed 25 Jan 2022 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 Mar 2021filed 29 Mar 2021 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 Mar 2021filed 29 Mar 2021 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 11 Jan 2021filed 19 Jan 2021 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $130K60,000 at $2.17 | filing |
| 9 Jan 2020filed 13 Jan 2020 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 5 Sep 2019filed 9 Sep 2019 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $99K30,000 at $3.30 | filing |
| 31 Jan 2019filed 4 Feb 2019 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $65K13,047 at $5.00 | filing |
| 30 Jan 2019filed 4 Feb 2019 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $85K16,953 at $5.00 | filing |
| 21 Jan 2019filed 23 Jan 2019 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —41,500 at $0.00 | filing |
| 21 Jan 2019filed 23 Jan 2019 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —62,250 at $0.00 | filing |
| 21 Jan 2019filed 23 Jan 2019 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | $37K41,500 at $0.89 | filing |
| 21 Jan 2019filed 23 Jan 2019 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code F | $37K7,776 at $4.75 | filing |
| 21 Jan 2019filed 23 Jan 2019 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | $149K62,250 at $2.39 | filing |
| 21 Jan 2019filed 23 Jan 2019 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code F | $149K31,322 at $4.75 | filing |
| 16 Jan 2019filed 18 Jan 2019 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 14 Dec 2017filed 18 Dec 2017 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,250 at $0.00 | filing |
News
Reviewing Atlassian (NASDAQ:TEAM) and InterDigital (NASDAQ:IDCC)IDCC · dailypolitical.com · 20 Oct 2026Financial Contrast: AT&T (NYSE:T) and GCI Liberty, Inc. – Series C GCI Group (NASDAQ:GLIBK)T · tickerreport.com · 18 Oct 2026Financial Analysis: InterDigital (NASDAQ:IDCC) versus Xperi (NYSE:XPER)IDCC · dailypolitical.com · 16 Oct 2026AT&T (NYSE:T) Stock Gets Price Target Trim from ScotiabankT · themarketsdaily.com · 12 Oct 2026InterDigital (NASDAQ:IDCC) versus LivePerson (NASDAQ:LPSN) Head-To-Head AnalysisIDCC · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Gilbert F. Amelio; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.